Evidence map›Paper›PMID 41872188›Full record

ArticleNature communications2026

Continuous evolution of a halogenase enzyme with improved solubility and activity for sustainable bioproduction.

Andre Arashiro Pulschen, Justin Booth, Ari Satanowski, Christelle Soudy, Joaquin Caro-Astorga, Osaid Ather, Namita Patel, Ali Alidoust, Samir Aoudjane, Lily Nematollahi and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Phage-assisted continuous evolution of enzymes for noncanonical tyrosine biosynthesis.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Andre Arashiro Pulschen *The Francis Crick Institute, London, UK.
Justin Booth *The Francis Crick Institute, London, UK.ORCID http://orcid.org/0009-0006-2031-1924
Ari SatanowskiThe Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-0775-4799
Christelle SoudyThe Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-2603-309X
Joaquin Caro-AstorgaThe Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-4650-6376
Osaid AtherThe Francis Crick Institute, London, UK.ORCID http://orcid.org/0000-0003-2476-0779
Namita PatelThe Francis Crick Institute, London, UK.
Ali AlidoustThe Francis Crick Institute, London, UK.
Samir AoudjaneThe Francis Crick Institute, London, UK.
Lily NematollahiThe Francis Crick Institute, London, UK.
Erika DeBenedictisThe Francis Crick Institute, London, UK. erika@biodesignlab.co.uk.ORCID http://orcid.org/0000-0002-7933-2651

Funding

Wellcome Trust CC2239
6 · The paper itself

Abstract

Halogenation enhances the stability and function of pharmaceuticals, biomaterials, and industrial compounds. However, chemical halogenation of molecules and peptides can lack stereoselectivity and require the use of toxic chemicals. Although enzymatic halogenation can improve selectivity and reduce environmental impact, current halogenases are inefficient and insoluble, leading to low yields that limit their applications. Here, we develop RebH

Indexed as

Directed Molecular EvolutionOxidoreductasesBioreactorsEscherichia coliHalogenationMutationSolubilityTryptophanOxidoreductasesTryptophantryptophan halogenase

Identifiers

PMID41872188
PMCPMC13171985

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.